Table 2.
Comparison of five main individual choline compound intakes between breast cancer cases and controls
| Choline compound | Cases (n = 807) | Controls (n = 807) | P a | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | P25 | P50 | P75 | Mean | SD | P25 | P50 | P75 | ||
| Free choline (mg/day) | 32.5 | 15.1 | 21.8 | 29.3 | 40.0 | 39.0 | 16.9 | 27.1 | 36.2 | 47.7 | <0.001 |
| Choline from glycerophosphocholine (mg/day) | 12.6 | 9.2 | 6.8 | 9.5 | 15.1 | 16.0 | 10.8 | 8.3 | 12.6 | 20.9 | <0.001 |
| Choline from phosphocholine (mg/day) | 12.4 | 7.8 | 7.2 | 10.7 | 15.5 | 15.1 | 8.5 | 9.5 | 13.7 | 18.9 | <0.001 |
| Choline from phosphatidylcholine (mg/day) | 84.9 | 46.0 | 52.9 | 74.0 | 106.8 | 98.0 | 49.0 | 60.9 | 91.8 | 125.4 | <0.001 |
| Choline from sphingomyelin (mg/day) | 4.5 | 3.3 | 2.2 | 3.8 | 6.0 | 5.4 | 3.9 | 2.6 | 4.6 | 7.4 | <0.001 |
a
Wilcoxon rank‐sum test comparing median consumption levels between cases and controls.
P25, P50 and P75 represent the 25th, 50th and 75th percentile, respectively.
SD, standard deviation.